EP0709680A1 - Magnetic particles with gelatin and immunoassay using the same - Google Patents

Magnetic particles with gelatin and immunoassay using the same Download PDF

Info

Publication number
EP0709680A1
EP0709680A1 EP94919875A EP94919875A EP0709680A1 EP 0709680 A1 EP0709680 A1 EP 0709680A1 EP 94919875 A EP94919875 A EP 94919875A EP 94919875 A EP94919875 A EP 94919875A EP 0709680 A1 EP0709680 A1 EP 0709680A1
Authority
EP
European Patent Office
Prior art keywords
gelatin
particles
magnetic particles
core
magnetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP94919875A
Other languages
German (de)
French (fr)
Other versions
EP0709680A4 (en
EP0709680B1 (en
Inventor
Mitsuo Isomura
Masayoshi Ueno
Kazuya Shimada
Yoshihiro Ashihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Inc
Original Assignee
Fujirebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Inc filed Critical Fujirebio Inc
Publication of EP0709680A1 publication Critical patent/EP0709680A1/en
Publication of EP0709680A4 publication Critical patent/EP0709680A4/en
Application granted granted Critical
Publication of EP0709680B1 publication Critical patent/EP0709680B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • G01N33/5434Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/10Magnetic particle immunoreagent carriers the magnetic material being used to coat a pre-existing polymer particle but not being present in the particle core
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/80Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/84Polymer coating, e.g. gelatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00Magnetic particle immunoreagent carriers
    • G01N2446/80Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids
    • G01N2446/90Magnetic particle immunoreagent carriers characterised by the agent used to coat the magnetic particles, e.g. lipids characterised by small molecule linker used to couple immunoreagents to magnetic particles

Definitions

  • This invention relates to magnetic particles and an immunoassay method using the same. More particularly, it relates to an immunoassay method which uses magnetic particles having a particle size of 1.0 to 10 ⁇ m and comprising an organic polymer material as a core, a magnetic material layer coating said core and gelatin coating said outer layer.
  • an immunoassay method in which particles produced by coating a magnetite core with a silane and having a particle size of 1.0 to 10 ⁇ m was used (Japanese Kokai Tokkyo Koho Sho-55-141670 and Sho-50-122997).
  • these known particles comprising a magnetic metal material as a core have some drawbacks. For instance, they are poorly uniform in particle size, or have poor long-storage stability as exemplified by iron migration.
  • particles comprising organic polymer materials as the core and a surface coating layer composed of an iron oxide-based ferrite and having a particle size of 0.2 to 3 ⁇ m and an immunoassay method using the same are known (Japanese Kokai Tokkyo Koho Hei-3-115862). Further, gelatin-ferrite particles produced by dispersing ferromagnetic fine particles in gelatin and having a particle size of 1.0 to 100 ⁇ m and an immunoassay method using the same are known (Japanese Kokai Tokkyo Koho Hei-3-17103).
  • magnetic particles comprising organic polymer materials as a core, a magnetic material layer formed to coat the core and a gelatin layer coating the surface of the magnetic material layer and having a particle size of 1.0 to 10 ⁇ m
  • the magnetic particles of this invention can be produced with ease and in a manner such that they have a desired particle size and are uniform in particle size as well. This fact, too, may be said to result in a high level of reproducibility.
  • This invention thus provides an immunoassay method using gelatin-coated magnetic particles comprising a core consisting of organic polymer materials, a magnetic material layer coating the surface of said core, and a gelatin layer coating the surface of said magnetic material layer and having a particle size of 1.0 to 10 ⁇ m.
  • the above-mentioned method coating with gelatin can be carried out by any method in general use in the art, for example by the chemical binding method utilizing the functional groups on the magnetic particle surface and of gelatin or by the technique of coacervation [T. N. Evreinova(author): "Coacervates", Modern Biology Series 22, Kyoritsu Shuppan].
  • the chemical binding method utilizing the functional groups on the magnetic particle surface and of gelatin can be carried out, for example, by subjecting the carboxyl, amino, hydroxyl and/or thiol groups on the magnetic particle surface and the amino or carboxyl groups of gelatin to be condensed by dehydration.
  • any condensing agent generally used in peptide bond formation reactions can be used.
  • examples are water-soluble carbodiimides and Woodward's reagents.
  • Coupling thiol groups on the magnetic particle surface to gelatin, the method comprising introducing in advance maleimide groups into gelatin and submitting the maleimidated gelatin to the reaction can be used, among others.
  • the method comprising coating the outer surface of magnetic particles with gelatin particles prepared by coacervation, using the chemical binding method, and the method which comprises carrying out coacervation of gelatin in the presence of magnetic particles, are applicable.
  • coacervation means coacervate formation, and "coacervate” means the whole system composed of a solute-rich phase and a solute-poor phase.
  • gelatin-coated magnetic particles In a process for producing the gelatin-coated magnetic particles as given by way of example, a solution containing gelatin (2 to 10%), a metaphosphate salt (0.01 to 5%), magnetic particles (0.3 to 1%) and a water-soluble polysaccharide (0 to 5%) are used and an acid is added to thereby adjust the pH to 2.5 to 6.0, whereupon coacervation occurs to give gelatin-coated magnetic particles. Then, the gelatin layer is reacted with an aldehyde cross linking agent for insolubilization of said outer layer.
  • Gelatin used for coating magnetic particles is a kind of derived protein and is obtained from collagen. Among various species, acid-treated gelatin having an isoelectric point of 6 to 9 is desirable.
  • the water-soluble polysaccharide for example, gum arabic, carboxymethylcellulose, sodium alginate, agar and carrageenan are usable.
  • the particle size measurement of particles in the dispersion medium can be performed using a particle size measuring apparatus employing the laser diffraction technique, for example an LA-500 apparatus (Horiba Seisakusho).
  • the gelatin-coated magnetic particles of this invention have a mean particle diameter of 1 to 10 ⁇ m.
  • the mean particle size is preferably within the range of 2 to 8 ⁇ m. Smaller particles in particle size than 1 ⁇ m require a long time for B/F separation and render it difficult to perform the assay in a simple and easy manner. Particles with a particle size exceeding 10 ⁇ m are disadvantageous in that the floatability becomes inferior, hence assays cannot be performed with high sensitivity.
  • the particle size of core is preferably within the range of 0.1 to 5 ⁇ m.
  • a particle size of the produced gelatin-coated magnetic particles will be larger than 10 ⁇ m.
  • the gelatin-coated magnetic particles will have a particle size smaller than 1 ⁇ m, rendering it impossible to conduct assays efficiently.
  • the organic polymer materials to be used as the core material for the gelatin-coated magnetic particles includes polystyrene, polymethacrylic esters, polyacrylic esters, styrene-methacrylic ester copolymers, styrene-acrylic ester copolymers, polymerized silanes and organic silanes, among others.
  • the magnetic material to form a core-coating layer is a magnetic metal material and use may be made of ferrite, manganese-, cobalt-, nickel- or like metal-containing ferrite species and the like.
  • the gelatin-coated magnetic particles of this invention can be used in immunoassay.
  • the antibody to be bound to the particles includes, among others, antibodies to drug substances such as theophylline, phenytoin and valproic acid, to low-molecular-weight hormones such as thyroxine, estrogen and estradiol, to cancer markers such as CEA and AFP, to viral antigens such as HIV, ATLA and HBV, to macromolecular hormones such as TSH and insulin, to cytokines such as IL-1, IL-2 and IL-6, to various growth factors such as EGF and PDGF, and, further, to appropriate DNAs, RNAs and the like of the viruses mentioned above.
  • the antigen to be used includes viruses such as HIV, ATLA and HBV, DNAs of such viruses and macromolecular hormones such as insulin and TSH, among others.
  • the physical adsorption method or the chemical binding method can be used for binding an antigen or antibody to the gelatin-coated magnetic particles.
  • the physical adsorption is carried out by reacting said particles with an antigen or antibody in an appropriate buffer solution.
  • the buffer to be used in this method is, for example, phosphate buffer, Tris-hydrochloride buffer, carbonate buffer or the like. When both materials are mixed at room temperature, the reaction readily progresses to give the desired product.
  • the carbodiimide method so called among peptide bond formation methods can be employed.
  • a water-soluble carbodiimide solution is added to an equal amount of a 0.1 to 5% dispersion of gelatin-coated magnetic particles under acidic conditions (pH 4 to 6)
  • the reaction is carried out at room temperature for 10 minutes to 1 hour, the supernatant is then removed, and an antibody or antigen solution having a concentration of 0.01 to 10.0 mg/ml, preferably 0.1 to 5 mg/ml, is added for binding of the antibody or antigen.
  • phosphate buffer and the like are preferred.
  • a bivalent crosslinking agent such as glutaric anhydride, N-succinimidyl-4-maleimidoburytic acid (GMBS), N-succinimidyl-4-(N-maleimidomethyl)cyclohexanecarboxylic acid (CHMS), glutaraldehyde or cyanuric chloride [cf. "Peputido Goseiho (Peptide Synthesis)", Maruzen Co.
  • the immunoassay method of this invention can be performed in the manner of radioimmunoassay or enzyme immunoassay, among others. These assay methods use a labeled antigen or antibody and the target antigen or antibody can be measured by the sandwich or competition technique.
  • antibody-bound gelatin-coated magnetic particles are reacted with an enzyme-labeled antibody and a sample for 1 minute to 18 hours.
  • the reaction temperature is within the range of 4°C to 40°C , preferably 25°C to 38°C .
  • the unreacted enzyme-labeled antibody is washed away, and that, an appropriate substrate is added and the activity of the antibody-bound enzyme bound to the solid phase is determined, whereby the ligand in the sample can be quantitated.
  • the enzyme to be used for labeling includes, among others, peroxidase, alkaline phosphatase, ⁇ -galactosidase and glucose oxidase.
  • the substrate to be used in the assay should, of course, be one adapted to the enzyme employed and, thus, includes, among others, ABTS, luminol-H2O2 (for peroxidase), p-nitrophenyl phosphate, methylumbelliferyl phosphate, 3-(2'-spiroadamantane)-4-methoxy-4-(3''-phosphoryloxy)phenyl-1,2-dioxetane (hereinafter referred to as AMPPD) (for alkaline phosphatase), p-nitrophenyl- ⁇ -O-galactose, methylumbelliferyl- ⁇ -O-galactose (for ⁇ - galactosidase), and the like.
  • AMPPD luminol-H2
  • the measurement of the quantitation is performed by allowing the reaction to proceed at 4°C to 40°C for 1 minute to 18 hours and then measuring the resulting color development, fluorescence intensity or luminescence intensity.
  • the so-called rate method to be conducted with warming in the range of 4°C to 40°C may also be employed.
  • the radioimmunoassay uses a radioisotope such as 125I as the label in lieu of the enzyme label mentioned above.
  • the procedure is generally the same as in the enzyme immunoassay mentioned above, except that radioactivity is measured.
  • Radiolabeling of antigens or antibodies can be readily performed using the Bolton-Hunter reagent already available on the market. Thus, for example, radiolabeling can be conducted with ease by adding said Bolton-Hunter reagent to an antigen or antibody solution in 0.1 M aqueous sodium hydrogen carbonate and, after the lapse of 1 to 2 hours, by removing the unreacted Bolton-Hunter reagent using a G-25 desalting column, for instance.
  • the chloramine T method or Iodogen method can also be employed for effecting 125I labeling with ease.
  • a sample is added to the gelatin-coated magnetic particles of this invention, and the mixture is maintained at 4°C to 40°C preferably 20°C to 38°C , for 1 minute to 18 hours. Then the particles are washed with physiological saline or distilled water, a raiolabeled antibody is added to the gelatin-coated magnetic particles, and the reaction is allowed to proceed at 4°C to 40°C , preferably 20°C to 38°C , for 1 minute to 18 hours, followed by washing with physiological saline or distilled water, and radioactivity is measured using a scintillation counter.
  • the assay method of this invention can also be performed in the manner of chemiluminescence assay or immunofluorescence assay.
  • isoluminol, an acridine ester or the like is used as the label and, in the latter, fluorescein, rhodamine or the like is used as the label.
  • labeling can easily be made using the activated ester method or isocyanate method ("Koso Men-eki Sokuteiho (Enzyme immunoassay)", Igaku Shoin,1987).
  • antigen-bound gelatin-coated magnetic particles according to this invention are mixed with a sample and the reaction is allowed to proceed at 4°C to 40°C for 1 minute to 18 hours, the particles are then washed with physiological saline or distilled water, a labeled anti-human immunoglobulin antibody or a labeled antigen is further added, the reaction is allowed to proceed at 4°C to 40°C for 1 minute to 18 hours, washing is conducted and the activity of the label is measured.
  • the immunoassay method according to the invention is the one that magnetic particles comprising an organic polymer core, a magnetic material layer coating the core and gelatin applied on the surface of the magnetic material layer are used.
  • This invension can be used as an immunoassay method capable of giving low-noise, high-signal data.
  • Fig. 1 shows comparative supernatant turbidity data obtained by placing magnetic particles, gelatin ferrite particles and gelatin-coated magnetic particles, in a dispersed form, in respective cells of a spectrophotometer and allowing the dispersions to stand.
  • Fig. 2 shows comparative supernatant turbidity data obtained by subjecting magnetic particles, gelatin ferrite particles and gelatin-coated magnetic particles, in a dispersed form, to magnetic separation.
  • Fig. 3 comparatively shows degrees of aggregation of alkaline phosphatase-bound magnetic particles and alkaline phosphatase-bound gelatin-coated magnetic particles as found after magnetic separation, standing, and addition of a substrate.
  • Fig. 4 comparatively shows degrees of aggregation of alkaline phosphatase-bound magnetic particles and alkaline phosphatase-bound gelatin-coated magnetic particles as found after magnetic separation, standing, and addition of a substrate.
  • Fig. 5 comparatively shows signal values obtained with magnetic particles and gelatin-coated magnetic particles.
  • Fig. 6 comparatively shows blank values obtained with magnetic particles and gelatin-coated magnetic particles.
  • Fig. 7 comparatively shows S/N ratios obtained with magnetic particles and gelatin-coated magnetic particles.
  • Fig. 8 comparatively shows signal values obtained with magnetic particles and gelatin-coated magnetic particles.
  • Fig. 9 comparatively shows blank values obtained with magnetic particles and gelatin-coated magnetic particles.
  • Fig. 10 comparatively shows S/N ratios obtained with magnetic particles and gelatin-coated magnetic particles.
  • a polymerization vessel equipped with a stirrer, thermometer, monomer dropping funnel, reflux condenser, heater and nitrogen gas inlet was charged with 230 parts of deionized water. Then, at 80°C , 1 part of a monomer mixture (A) composed of styrene, 2-ethylhexyl acrylate and ethylene glycol dimethacrylate in the proportions of 80/10/10 and 10 parts of a 10% aqueous ammonium persulfate solution were added and then 99 parts of the same monomer mixture (A) as mentioned above was added dropwise over 3 hours, whereupon macromolecule particles were obtained. Electron microscopy revealed that these particles were practically in a monodisperse state and had a particle size of 0.3 ⁇ m.
  • a magnetic material formation apparatus equipped with a stirrer, thermometer, oxidizing agent solution, dropping funnel, heater and nitrogen gas inlet tube was charged with 100 parts of the organic polymer materials particle emulsion obtained as mentioned above (solid content: 30%). Nitrogen gas was introduced thereinto for freeing the core emulsion from oxygen.
  • Acid-treated gelatin (0.4 g) with an isoelectric point of pH 9 was dissolved in 20 ml of warm water at 40°C , and the solution was adjusted to pH 9 with sodium hydroxide.
  • This mixed solution was poured into 15 ml of 30% (by volume) ethyl alcohol solution warmed in advance to 40°C , followed by thorough stirring.
  • To this were added 80 ⁇ l of 10% sodium hexametaphosphate solution, 0.1 ml of 10% alkyl sulfomaleate and 0.2 g of the magnetic particles produced in Example 2, followed by thorough stirring.
  • Acid-treated gelatin (0.4 g) with an isoelectric point of pH 9 was dissolved in 10 ml of warm water at 40°C , and the solution was adjusted to pH 9 with sodium hydroxide.
  • To this solution was added 0.4 g of gum arabic dissolved in 10 ml of water as warmed to 40°C , followed by thorough stirring.
  • This mixed solution was poured into 15 ml of 30% (by volume) ethyl alcohol solution warmed in advance to 40°C , followed by thorough stirring.
  • 80 ⁇ l of 10% sodium hexametaphosphate solution 0.1 ml of 10% alkyl sulfomaleate and 0.2 g of the magnetic particles produced in Example 2, followed by thorough stirring.
  • gelatin-coated magnetic particles produced in Example 3 were dispersed in gelatin (Japanese Kokai Tokkyo Koho Hei-3-17103) (for comparison) were respectively dispersed, in a concentration of 0.015%, in 100 mM Tris-hydrochloride-150 mM NaCl buffer (pH 7.2) containing 2% BSA (bovine serum albumin).
  • BSA bovine serum albumin
  • One ml of each dispersion was placed in a cell for a spectrophotometer (Hitachi) and allowed to stand at room temperature. After 5 to 40 minutes, the turbidity of the supernatant was determined by measuring the absorbance at wavelength 660 nm. The relative turbidity data thus obtained are shown in Fig. 1.
  • gelatin-coated magnetic particles produced in Example 3 the magnetic particles produced in Example 2 (for comparison) and gelatin-ferrite particles with ferromagnetic particles were dispersed in gelatin (Japanese Kokai Tokkyo Koho Hei-3-17103) (for comparison) were respectively dispersed, in a concentration of 0.015%, in 100 mM Tris-hydrochloride-150 mM NaCl buffer (pH 7.2) containing 2% BSA.
  • One ml of each dispersion was placed in a tube and the tube was brought into contact with a magnet with a surface magnetic field strength of 1000 gauss. After 15 seconds to 2 minutes of contacting with a magnet, the turbidity of the supernatant was determined by measuring the absorbance at wavelength 660 nm.
  • the relative turbidity data thus obtained are shown in Fig. 2.
  • a 250- ⁇ l portion of a dispersion (0.015%) of the magnetic particles produced in Example 2 or the gelatin-coated magnetic particles produced in Example 3 as bound with alkaline phosphatase was placed in a cartridge and subjected to magnetic separation by contacting the cartridge with a magnet, and the supernatant was removed. Further, washing was performed by adding 300 ⁇ l of 0.9% NaCl, followed by magnetic separation. Washing was further repeated two times with 0.9% NaCl and three times with distilled water. The particles separated as magnetically were allowed to stand at room temperature for 0 to 30 minutes. Then, the luminescent substrate, AMPPD, was added and the reaction was allowed to proceed at 37°C for 5 minutes.
  • AMPPD luminescent substrate
  • Example 3 A 100-mg portion of the gelatin-coated magnetic particles produced in Example 3 were washed three times each with distilled water, water and distilled water, then 50 mg of glutaric anhydride suspended to 5% by volume in 0.1M sodium hydrogen carbonate was added thereto, and the reaction was allowed to proceed for 10 minutes. Thereafter, the particles were washed three times with 0.1 M sodium hydrogen carbonate solution and five times with distilled water. The particles thus obtained are referred to as carboxylated particles.
  • a 25-mg portion of the carboxylated particles produced in Example 8 were dispersed in 2.5 ml of 10 mM phosphate buffer (pH 4.5), and 25 mg of a water-soluble carbodiimide was added to the dispersion. After allowing the reaction to proceed at room temperature for 20 minutes, the supernatant was removed, 2.5 ml of an anti-AFP antibody solution (1 mg/ml, 20 mM phosphate buffer, pH 4.5) was added, and the mixture was stirred with an end-over-end mixer. After 2 hours, the particles were washed five times with a 2% BSA solution (0.1 M Tris-hydrochloride, 1 mM MgCl2, pH 7.5) and then dispersed in the same BSA solution.
  • a 2% BSA solution 0.1 M Tris-hydrochloride, 1 mM MgCl2, pH 7.5
  • a cartridge 10 ⁇ l of a sample containing 200 ng/ml of AFP antigen was mixed with 250 ⁇ l of the dispersion of the carboxylated particles bound to anti-AFP antibody prepared in Example 9, and the reaction was allowed to proceed at 37°C for 10 minutes.
  • the cartridge was contacted with a magnet with a surface magnetic field with strength of 3000 gauss to thereby cause magnetic separation of the particles.
  • the supernatant was removed by decantation.
  • Three hundred ⁇ l of physiological saline was added to the particles and, after stirring and magnetic separation, the supernatant was discarded by decantation. This procedure was repeated three times.
  • the particles were mixed with 250 ⁇ l of the solution of an alkaline phosphatase bound anti-AFP antibodies (Fab') (0.1 ⁇ g/ml, 0.1 M Tris-hydrochloride, 1 mM MgCl2, 0.1 mM ZnCl2), and the reaction was allowed to proceed at 37°C for 10 minutes.
  • the particles were washed by decantation using physiological saline.
  • the magnetic particles produced in Example 2 was aminosilanated, then carboxylated, and then, anti-AFP antibodies were bound to the particles, which were then used for assaying AFP.
  • the obtained results are shown in Figs. 5, 6 and 7.
  • Signal values are given in Fig. 5.
  • a 20-mg portion of the gelatin-coated magnetic particles prepared in Example 3 was dispersed in 4 ml of 100 mM sodium phosphate buffer (pH 7.0), and 2 ml of a GMBS solution (1 mg/ml, ethanol) was added, and the mixture was stirred in an end-over-end manner. After an hour, 2 ml of the same GMBS solution was added and the mixture was stirred in an end-over-end manner. After an hour, the particles were washed three times with ethanol and further three times with 100 mM sodium phosphate buffer (pH 7.0).
  • the particles were washed three times with 50 mM sodium phosphate buffer (1 mM EDTA ⁇ 2Na, pH 7.0) and further three times with a 2% BSA solution (50 mM Tris-hydrochloride, 0.15 M sodium chloride, 1 mM EDTA ⁇ 2Na, pH 7.2) and then were dispersed in the same 2% BSA solution to give a TP antigen bound particle dispersion.
  • 50 mM sodium phosphate buffer (1 mM EDTA ⁇ 2Na, pH 7.0
  • a 2% BSA solution 50 mM Tris-hydrochloride, 0.15 M sodium chloride, 1 mM EDTA ⁇ 2Na, pH 7.2
  • the obtained signal value is shown in Fig. 8, the blank value (noise value) in Fig. 9 and the S/N ratio in Fig. 10.
  • the magnetic particles to be used in immunoassay in accordance with this invention are each composed of a core essentailly consisting of organic polymer materials, a magnetic material layer coating the core, and gelatin on the surface of said magnetic material layer and, therefore, are substantially free of iron migration and very stable against a prolonged period of storage. They are excellent in magnetic response and hardly undergo self aggregation, so that they can be expected to conform satisfactorily to rapid B/F separation and washing requirements. Therefore, the method of this invention can give low-noise, high-signal assay results.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
  • Hard Magnetic Materials (AREA)

Abstract

This invention intends to provide an immunoassay for obtaining stable measuring results which provide low noises and high signals, characterized by use of gelatin-coated magnetic particles whose diameters range from 1.0 to 10 µm and each having a core of an organic polymer material, a layer formed from a magnetic material so as to coat the exterior of the core and gelatin coating the surface of the layer formed from the magnetic material.

Description

    FIELD OF THE INVENTION
  • This invention relates to magnetic particles and an immunoassay method using the same. More particularly, it relates to an immunoassay method which uses magnetic particles having a particle size of 1.0 to 10 µm and comprising an organic polymer material as a core, a magnetic material layer coating said core and gelatin coating said outer layer.
  • BACKGROUND OF THE INVENTION
  • In immunoassay, in particular enzyme immunoassays, beads having a fairly large diameter have so far been used as the solid phase. It is known that a reduction in their size and an increase in solid phase surface area are advantageously conductive to high levels of sensitivity in carrying out immunological reactions.
  • However, when particles having a smaller diameter are used, a centrifuge must be used or filtration using a filter must be made for B/F separation, so that the assay method can hardly be said to be simple and easy. Therefore, for carrying out B/F separation efficiently and simply, it has been proposed that magnetic particles small in diameter are employed.
  • Thus, for instance, an immunoassay method is known in which particles produced by coating a magnetite core with a silane and having a particle size of 1.0 to 10 µm was used (Japanese Kokai Tokkyo Koho Sho-55-141670 and Sho-50-122997).
  • Another immunoassay method was known in which particles produced by coating a magnetic metal oxide core with a silane and having a particle size of 0.1 to 1.5 µm was used (Japanese Kokai Tokkyo Koho Sho-60-1564).
  • However, these known particles comprising a magnetic metal material as a core have some drawbacks. For instance, they are poorly uniform in particle size, or have poor long-storage stability as exemplified by iron migration.
  • Accordingly, attempts have been made to improve the particles and stabilize them against long-period storage. Thus, for instance, particles comprising organic polymer materials as the core and a surface coating layer composed of an iron oxide-based ferrite and having a particle size of 0.2 to 3 µm and an immunoassay method using the same are known (Japanese Kokai Tokkyo Koho Hei-3-115862). Further, gelatin-ferrite particles produced by dispersing ferromagnetic fine particles in gelatin and having a particle size of 1.0 to 100 µm and an immunoassay method using the same are known (Japanese Kokai Tokkyo Koho Hei-3-17103).
  • Furthermore, an immune complex transfer assay method has been proposed for the purpose of attaining noise reduction (Tanpakushitsu, Kakusan, Koso, vol. 37, pp. 144).
  • DISCLOSURE OF THE INVENTION
  • The magnetic particles comprising organic polymer materials as a core and an iron oxide-based ferrite surface layer have indeed improved in long-storage stability but some problems have still been unsolved. For instance, they are inferior in floatability at the time of immune reaction and show a tendency toward particle aggregation at the time of B/F separation in the process of immunoassay and, furthermore, have poor redispersibility. As regards the gelatin ferrite particles produced by dispersing ferromagnetic fine particles in gelatin, the problem of particle aggregation has been solved but, however, their magnetic response property is poor, hence they are not suited for immunoassay, particularly, in enzyme immunoassay, in which rapid B/F separation and washing are required. The immune complex transfer assay method is not practical since it includes an increased number of procedural steps and required a fairly long assay time.
  • This inventors made earnest efforts to solve these problems and found that magnetic particles comprising organic polymer materials as a core, a magnetic material layer formed to coat the core and a gelatin layer coating the surface of the magnetic material layer and having a particle size of 1.0 to 10 µm, when used in immunoassay, can result in low-noise and high-signal in the assay, owing to the fact that the magnetic particles are stable over a long period of time, thus can be stored for a long period, have been improved in the floatability, furthermore, hardly tend to undergo self-aggregation and show sufficient magnetic response and dispersibility to enable rapid B/F separation and washing. Furthermore, the magnetic particles of this invention can be produced with ease and in a manner such that they have a desired particle size and are uniform in particle size as well. This fact, too, may be said to result in a high level of reproducibility.
  • This invention thus provides an immunoassay method using gelatin-coated magnetic particles comprising a core consisting of organic polymer materials, a magnetic material layer coating the surface of said core, and a gelatin layer coating the surface of said magnetic material layer and having a particle size of 1.0 to 10 µm.
  • As the magnetic particles that can be used in the method of this invention, there may be mentioned, for example, those produced by using magnetic particles comprising a layer formed from a magnetic material on the surface of a core made of organic polymer materials and coating said magnetic particles with gelatin. (Hereinafter such particles are referred to as gelatin-coated magnetic particles.)
  • The above-mentioned method coating with gelatin can be carried out by any method in general use in the art, for example by the chemical binding method utilizing the functional groups on the magnetic particle surface and of gelatin or by the technique of coacervation [T. N. Evreinova(author): "Coacervates", Modern Biology Series 22, Kyoritsu Shuppan].
  • The chemical binding method utilizing the functional groups on the magnetic particle surface and of gelatin can be carried out, for example, by subjecting the carboxyl, amino, hydroxyl and/or thiol groups on the magnetic particle surface and the amino or carboxyl groups of gelatin to be condensed by dehydration.
  • For the dehydration, any condensing agent generally used in peptide bond formation reactions can be used. Examples are water-soluble carbodiimides and Woodward's reagents. Coupling thiol groups on the magnetic particle surface to gelatin, the method comprising introducing in advance maleimide groups into gelatin and submitting the maleimidated gelatin to the reaction can be used, among others.
  • As coating gelatin by coacervation, the method comprising coating the outer surface of magnetic particles with gelatin particles prepared by coacervation, using the chemical binding method, and the method which comprises carrying out coacervation of gelatin in the presence of magnetic particles, are applicable.
  • The term "coacervation" as used herein means coacervate formation, and "coacervate" means the whole system composed of a solute-rich phase and a solute-poor phase.
  • While two types of coacervation, simple and complex, are distinguishable depending on the conditions, either type may be used in producing the particles of this invention.
  • In simple coacervation, the phenomenon was used that the solubility of the organic polymer decreases and phase separation occurs of said organic polymer from the aqueous solution, for instance, when an electrolyte or an organic solvent is added to a solution of an organic polymer or when the pH of a solution of an organic polymer becomes equal to the isoelectric point of the organic polymer. In complex coacervation, an electric interaction resulting from the combination of a polycation and a polyanion causes coacervation. In this case, the mixing ratio between the polycation and polyanion, the initial concentration, the coexisting salt and the concentration thereof, and the pH are determining factors.
  • In a process for producing the gelatin-coated magnetic particles as given by way of example, a solution containing gelatin (2 to 10%), a metaphosphate salt (0.01 to 5%), magnetic particles (0.3 to 1%) and a water-soluble polysaccharide (0 to 5%) are used and an acid is added to thereby adjust the pH to 2.5 to 6.0, whereupon coacervation occurs to give gelatin-coated magnetic particles. Then, the gelatin layer is reacted with an aldehyde cross linking agent for insolubilization of said outer layer. Gelatin used for coating magnetic particles is a kind of derived protein and is obtained from collagen. Among various species, acid-treated gelatin having an isoelectric point of 6 to 9 is desirable. As the water-soluble polysaccharide, for example, gum arabic, carboxymethylcellulose, sodium alginate, agar and carrageenan are usable.
  • The particle size measurement of particles in the dispersion medium can be performed using a particle size measuring apparatus employing the laser diffraction technique, for example an LA-500 apparatus (Horiba Seisakusho). The gelatin-coated magnetic particles of this invention have a mean particle diameter of 1 to 10 µm. For more efficient immunoassay, however, the mean particle size is preferably within the range of 2 to 8 µm. Smaller particles in particle size than 1 µm require a long time for B/F separation and render it difficult to perform the assay in a simple and easy manner. Particles with a particle size exceeding 10 µm are disadvantageous in that the floatability becomes inferior, hence assays cannot be performed with high sensitivity.
  • For producing gelatin-coated magnetic particles having a particle size of 1 to 10 µm, the particle size of core is preferably within the range of 0.1 to 5 µm. When a core having a particle size larger than 5 µm are used, a particle size of the produced gelatin-coated magnetic particles will be larger than 10 µm. When a core having a particle size smaller than 0.1 µm are used, the gelatin-coated magnetic particles will have a particle size smaller than 1 µm, rendering it impossible to conduct assays efficiently. The organic polymer materials to be used as the core material for the gelatin-coated magnetic particles includes polystyrene, polymethacrylic esters, polyacrylic esters, styrene-methacrylic ester copolymers, styrene-acrylic ester copolymers, polymerized silanes and organic silanes, among others.
  • The magnetic material to form a core-coating layer is a magnetic metal material and use may be made of ferrite, manganese-, cobalt-, nickel- or like metal-containing ferrite species and the like.
  • When an antibody or antigen is bound thereto, the gelatin-coated magnetic particles of this invention can be used in immunoassay. The antibody to be bound to the particles includes, among others, antibodies to drug substances such as theophylline, phenytoin and valproic acid, to low-molecular-weight hormones such as thyroxine, estrogen and estradiol, to cancer markers such as CEA and AFP, to viral antigens such as HIV, ATLA and HBV, to macromolecular hormones such as TSH and insulin, to cytokines such as IL-1, IL-2 and IL-6, to various growth factors such as EGF and PDGF, and, further, to appropriate DNAs, RNAs and the like of the viruses mentioned above. The antigen to be used includes viruses such as HIV, ATLA and HBV, DNAs of such viruses and macromolecular hormones such as insulin and TSH, among others.
  • For binding an antigen or antibody to the gelatin-coated magnetic particles, the physical adsorption method or the chemical binding method can be used. The physical adsorption is carried out by reacting said particles with an antigen or antibody in an appropriate buffer solution. The buffer to be used in this method is, for example, phosphate buffer, Tris-hydrochloride buffer, carbonate buffer or the like. When both materials are mixed at room temperature, the reaction readily progresses to give the desired product. In the case of chemical binding, the carbodiimide method so called among peptide bond formation methods can be employed. Thus, for instance, for effecting the reaction, a water-soluble carbodiimide solution is added to an equal amount of a 0.1 to 5% dispersion of gelatin-coated magnetic particles under acidic conditions (pH 4 to 6), the reaction is carried out at room temperature for 10 minutes to 1 hour, the supernatant is then removed, and an antibody or antigen solution having a concentration of 0.01 to 10.0 mg/ml, preferably 0.1 to 5 mg/ml, is added for binding of the antibody or antigen. As the buffer to be used on that occasion, phosphate buffer and the like are preferred. It is also possible to effect the chemical binding according to other methods in the presence of a bivalent crosslinking agent such as glutaric anhydride, N-succinimidyl-4-maleimidoburytic acid (GMBS), N-succinimidyl-4-(N-maleimidomethyl)cyclohexanecarboxylic acid (CHMS), glutaraldehyde or cyanuric chloride [cf. "Peputido Goseiho (Peptide Synthesis)", Maruzen Co. (1975); "Koso Men-eki Sokuteiho (Enzyme immunoassay)", Kyoritsu Shuppan; "Tanpakushitsu, kakusan, Koso (Protein, Nucleic acid, Enzyme)", Supplement No. 31 (1987)].
  • The immunoassay method of this invention can be performed in the manner of radioimmunoassay or enzyme immunoassay, among others. These assay methods use a labeled antigen or antibody and the target antigen or antibody can be measured by the sandwich or competition technique.
  • In the enzyme immunoassay method, antibody-bound gelatin-coated magnetic particles are reacted with an enzyme-labeled antibody and a sample for 1 minute to 18 hours. The reaction temperature is within the range of 4°C to 40°C , preferably 25°C to 38°C . The unreacted enzyme-labeled antibody is washed away, and that, an appropriate substrate is added and the activity of the antibody-bound enzyme bound to the solid phase is determined, whereby the ligand in the sample can be quantitated.
  • The enzyme to be used for labeling includes, among others, peroxidase, alkaline phosphatase, β -galactosidase and glucose oxidase. The substrate to be used in the assay should, of course, be one adapted to the enzyme employed and, thus, includes, among others, ABTS, luminol-H₂O₂ (for peroxidase), p-nitrophenyl phosphate, methylumbelliferyl phosphate, 3-(2'-spiroadamantane)-4-methoxy-4-(3''-phosphoryloxy)phenyl-1,2-dioxetane (hereinafter referred to as AMPPD) (for alkaline phosphatase), p-nitrophenyl- β -O-galactose, methylumbelliferyl-β -O-galactose (for β - galactosidase), and the like.
  • The measurement of the quantitation is performed by allowing the reaction to proceed at 4°C to 40°C for 1 minute to 18 hours and then measuring the resulting color development, fluorescence intensity or luminescence intensity. For the measurement, the so-called rate method to be conducted with warming in the range of 4°C to 40°C may also be employed.
  • The radioimmunoassay uses a radioisotope such as ¹²⁵I as the label in lieu of the enzyme label mentioned above. The procedure is generally the same as in the enzyme immunoassay mentioned above, except that radioactivity is measured.
  • Radiolabeling of antigens or antibodies can be readily performed using the Bolton-Hunter reagent already available on the market. Thus, for example, radiolabeling can be conducted with ease by adding said Bolton-Hunter reagent to an antigen or antibody solution in 0.1 M aqueous sodium hydrogen carbonate and, after the lapse of 1 to 2 hours, by removing the unreacted Bolton-Hunter reagent using a G-25 desalting column, for instance.
  • The chloramine T method or Iodogen method, for instance, can also be employed for effecting ¹²⁵I labeling with ease.
  • For allowing the immune reaction to proceed, a sample is added to the gelatin-coated magnetic particles of this invention, and the mixture is maintained at 4°C to 40°C preferably 20°C to 38°C , for 1 minute to 18 hours. Then the particles are washed with physiological saline or distilled water, a raiolabeled antibody is added to the gelatin-coated magnetic particles, and the reaction is allowed to proceed at 4°C to 40°C , preferably 20°C to 38°C , for 1 minute to 18 hours, followed by washing with physiological saline or distilled water, and radioactivity is measured using a scintillation counter.
  • The assay method of this invention can also be performed in the manner of chemiluminescence assay or immunofluorescence assay. In the former, isoluminol, an acridine ester or the like is used as the label and, in the latter, fluorescein, rhodamine or the like is used as the label. In these cases, labeling can easily be made using the activated ester method or isocyanate method ("Koso Men-eki Sokuteiho (Enzyme immunoassay)", Igaku Shoin,1987).
  • Similarly, in an example of antibody assaying, antigen-bound gelatin-coated magnetic particles according to this invention are mixed with a sample and the reaction is allowed to proceed at 4°C to 40°C for 1 minute to 18 hours, the particles are then washed with physiological saline or distilled water, a labeled anti-human immunoglobulin antibody or a labeled antigen is further added, the reaction is allowed to proceed at 4°C to 40°C for 1 minute to 18 hours, washing is conducted and the activity of the label is measured.
  • As mentioned above, the immunoassay method according to the invention is the one that magnetic particles comprising an organic polymer core, a magnetic material layer coating the core and gelatin applied on the surface of the magnetic material layer are used. This invension can be used as an immunoassay method capable of giving low-noise, high-signal data.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • Fig. 1 shows comparative supernatant turbidity data obtained by placing magnetic particles, gelatin ferrite particles and gelatin-coated magnetic particles, in a dispersed form, in respective cells of a spectrophotometer and allowing the dispersions to stand.
  • Fig. 2 shows comparative supernatant turbidity data obtained by subjecting magnetic particles, gelatin ferrite particles and gelatin-coated magnetic particles, in a dispersed form, to magnetic separation.
  • Fig. 3 comparatively shows degrees of aggregation of alkaline phosphatase-bound magnetic particles and alkaline phosphatase-bound gelatin-coated magnetic particles as found after magnetic separation, standing, and addition of a substrate.
  • Fig. 4 comparatively shows degrees of aggregation of alkaline phosphatase-bound magnetic particles and alkaline phosphatase-bound gelatin-coated magnetic particles as found after magnetic separation, standing, and addition of a substrate.
  • Fig. 5 comparatively shows signal values obtained with magnetic particles and gelatin-coated magnetic particles.
  • Fig. 6 comparatively shows blank values obtained with magnetic particles and gelatin-coated magnetic particles.
  • Fig. 7 comparatively shows S/N ratios obtained with magnetic particles and gelatin-coated magnetic particles.
  • Fig. 8 comparatively shows signal values obtained with magnetic particles and gelatin-coated magnetic particles.
  • Fig. 9 comparatively shows blank values obtained with magnetic particles and gelatin-coated magnetic particles.
  • Fig. 10 comparatively shows S/N ratios obtained with magnetic particles and gelatin-coated magnetic particles.
  • BEST MODES FOR CARRYING OUT THE INVENTION
  • The following examples are further illustrative of this invention.
  • Example 1 [Production of macromolecule particles]
  • A polymerization vessel equipped with a stirrer, thermometer, monomer dropping funnel, reflux condenser, heater and nitrogen gas inlet was charged with 230 parts of deionized water. Then, at 80°C , 1 part of a monomer mixture (A) composed of styrene, 2-ethylhexyl acrylate and ethylene glycol dimethacrylate in the proportions of 80/10/10 and 10 parts of a 10% aqueous ammonium persulfate solution were added and then 99 parts of the same monomer mixture (A) as mentioned above was added dropwise over 3 hours, whereupon macromolecule particles were obtained. Electron microscopy revealed that these particles were practically in a monodisperse state and had a particle size of 0.3 µm.
  • Example 2 [Production of magnetic particles]
  • A magnetic material formation apparatus equipped with a stirrer, thermometer, oxidizing agent solution, dropping funnel, heater and nitrogen gas inlet tube was charged with 100 parts of the organic polymer materials particle emulsion obtained as mentioned above (solid content: 30%). Nitrogen gas was introduced thereinto for freeing the core emulsion from oxygen.
  • Then, 100 parts of a ferrous chloride solution (solid content: 40 parts) and 150 parts of ammonium acetate (solid content: 75 parts), each prepared in advance were charged into the apparatus and the contents were heated to 70°C with thorough stirring. Thereafter, the pH was adjusted to 7.2 with aqueous ammonia while stirring was continued.
  • One hundred fifty parts of a sodium nitrite solution (solid content: 15 parts) was added by dropwise to the resultant over about 1 hour. During the dropping, the liquid phase was maintained, with continued nitrogen gas introduction and stirring, at a temperature of 70°C and a pH within the range of 7.0 to 7.2 to form a ferrite coating on the surface of said particles. After about 20 minutes, the solution was cooled and filtered, and the solid was repeatedly washed with deionized water. Ferrite magnetic particles were thus recovered.
  • Example 3
  • Acid-treated gelatin (0.4 g) with an isoelectric point of pH 9 was dissolved in 20 ml of warm water at 40°C , and the solution was adjusted to pH 9 with sodium hydroxide. This mixed solution was poured into 15 ml of 30% (by volume) ethyl alcohol solution warmed in advance to 40°C , followed by thorough stirring. To this were added 80 µl of 10% sodium hexametaphosphate solution, 0.1 ml of 10% alkyl sulfomaleate and 0.2 g of the magnetic particles produced in Example 2, followed by thorough stirring. Then, the mixture was adjusted to pH 5.0 by dropwise addition of 10% (by volume) acetic acid solution while the mixture was maintained at 40°C Glutaraldehyde (65 mg) was added to the thus-formed particle dispersion while the latter was maintained at 4°C . The resultant mixture was stirred and then allowed to stand at 4 °C overnight. This was washed with 0.9% NaCl and then made up into a 10% particle dispersion with 0.9% NaCl. An equal volume of 4% (by volume) formaldehyde solution was added and, after dispersion, the mixture was allowed to stand at 4°C for 1 week. Measurement with an LA-500 apparatus revealed that the thus-obtained gelatin-coated magnetic particles had a mean diameter of 6.2 µm.
  • Example 4
  • Acid-treated gelatin (0.4 g) with an isoelectric point of pH 9 was dissolved in 10 ml of warm water at 40°C , and the solution was adjusted to pH 9 with sodium hydroxide. To this solution was added 0.4 g of gum arabic dissolved in 10 ml of water as warmed to 40°C , followed by thorough stirring. This mixed solution was poured into 15 ml of 30% (by volume) ethyl alcohol solution warmed in advance to 40°C , followed by thorough stirring. To this were added 80 µl of 10% sodium hexametaphosphate solution, 0.1 ml of 10% alkyl sulfomaleate and 0.2 g of the magnetic particles produced in Example 2, followed by thorough stirring. Then, the mixture was adjusted to pH 5.0 by dropwise addition of 10% (by volume) acetic acid solution while the mixture was maintained at 40°C Glutaraldehyde (65 mg) was added to the thus-formed particle dispersion while the latter was maintained at 4°C . The resultant mixture was stirred well and then allowed to stand at 4°C overnight. This was washed with 0.9% NaCl and then made up into a 10% particle dispersion with 0.9% NaCl. An equal volume of 4% (by volume) formaldehyde solution was added and, after effecting dispersion, the mixture was allowed to stand at 4°C for 1 week. Measurement with an LA-500 apparatus revealed that the thus-obtained gelatin-coated magnetic particles had a mean diameter of 4.7 µm.
  • Example 5 [Investigation on particle floatability]
  • The gelatin-coated magnetic particles produced in Example 3, the magnetic particles produced in Example 2 (for comparison) and gelatin-ferrite particles with ferromagnetic particles were dispersed in gelatin (Japanese Kokai Tokkyo Koho Hei-3-17103) (for comparison) were respectively dispersed, in a concentration of 0.015%, in 100 mM Tris-hydrochloride-150 mM NaCl buffer (pH 7.2) containing 2% BSA (bovine serum albumin). One ml of each dispersion was placed in a cell for a spectrophotometer (Hitachi) and allowed to stand at room temperature. After 5 to 40 minutes, the turbidity of the supernatant was determined by measuring the absorbance at wavelength 660 nm. The relative turbidity data thus obtained are shown in Fig. 1.
  • Example 6 [Comparison of particle species with respect to magnetic separability]
  • The gelatin-coated magnetic particles produced in Example 3, the magnetic particles produced in Example 2 (for comparison) and gelatin-ferrite particles with ferromagnetic particles were dispersed in gelatin (Japanese Kokai Tokkyo Koho Hei-3-17103) (for comparison) were respectively dispersed, in a concentration of 0.015%, in 100 mM Tris-hydrochloride-150 mM NaCl buffer (pH 7.2) containing 2% BSA. One ml of each dispersion was placed in a tube and the tube was brought into contact with a magnet with a surface magnetic field strength of 1000 gauss. After 15 seconds to 2 minutes of contacting with a magnet, the turbidity of the supernatant was determined by measuring the absorbance at wavelength 660 nm. The relative turbidity data thus obtained are shown in Fig. 2.
  • Example 7 [Comparison of particle species with respect to aggregation tendency under drying conditions]
  • A 250-µl portion of a dispersion (0.015%) of the magnetic particles produced in Example 2 or the gelatin-coated magnetic particles produced in Example 3 as bound with alkaline phosphatase was placed in a cartridge and subjected to magnetic separation by contacting the cartridge with a magnet, and the supernatant was removed. Further, washing was performed by adding 300 µl of 0.9% NaCl, followed by magnetic separation. Washing was further repeated two times with 0.9% NaCl and three times with distilled water. The particles separated as magnetically were allowed to stand at room temperature for 0 to 30 minutes. Then, the luminescent substrate, AMPPD, was added and the reaction was allowed to proceed at 37°C for 5 minutes. Immediately thereafter, the luminescence intensity was measured using a luminometer (ALOKA). The relations thus obtained between particles drying (standing) time and signal value are shown in Fig. 3. A photograph of dispersion of said particles as supplemented with the luminescent substrate and placed on an ELISA plate is shown in Fig. 4.
  • Example 8 [Carboxylation of particles]
  • A 100-mg portion of the gelatin-coated magnetic particles produced in Example 3 were washed three times each with distilled water, water and distilled water, then 50 mg of glutaric anhydride suspended to 5% by volume in 0.1M sodium hydrogen carbonate was added thereto, and the reaction was allowed to proceed for 10 minutes. Thereafter, the particles were washed three times with 0.1 M sodium hydrogen carbonate solution and five times with distilled water. The particles thus obtained are referred to as carboxylated particles.
  • Example 9 [Preparation of anti-AFP antibody bound carboxylated particles]
  • A 25-mg portion of the carboxylated particles produced in Example 8 were dispersed in 2.5 ml of 10 mM phosphate buffer (pH 4.5), and 25 mg of a water-soluble carbodiimide was added to the dispersion. After allowing the reaction to proceed at room temperature for 20 minutes, the supernatant was removed, 2.5 ml of an anti-AFP antibody solution (1 mg/ml, 20 mM phosphate buffer, pH 4.5) was added, and the mixture was stirred with an end-over-end mixer. After 2 hours, the particles were washed five times with a 2% BSA solution (0.1 M Tris-hydrochloride, 1 mM MgCl₂, pH 7.5) and then dispersed in the same BSA solution.
  • Example 10 [AFP assay using anti-AFP antibody bound carboxylated particles]
  • In a cartridge, 10 µl of a sample containing 200 ng/ml of AFP antigen was mixed with 250 µl of the dispersion of the carboxylated particles bound to anti-AFP antibody prepared in Example 9, and the reaction was allowed to proceed at 37°C for 10 minutes. The cartridge was contacted with a magnet with a surface magnetic field with strength of 3000 gauss to thereby cause magnetic separation of the particles. The supernatant was removed by decantation. Three hundred µl of physiological saline was added to the particles and, after stirring and magnetic separation, the supernatant was discarded by decantation. This procedure was repeated three times. Then, the particles were mixed with 250 µl of the solution of an alkaline phosphatase bound anti-AFP antibodies (Fab') (0.1 µg/ml, 0.1 M Tris-hydrochloride, 1 mM MgCl₂, 0.1 mM ZnCl₂), and the reaction was allowed to proceed at 37°C for 10 minutes. The particles were washed by decantation using physiological saline. A substrate solution containing 200 µg/ml of the luminescent substrate, AMPPD (0.1 M DEA-hydrochloride, 1 mM MgCl₂, pH 10.0), was added to the cartridge containing the particles treated as above, and the reaction was allowed to proceed at 37°C for 5 minutes. Thereafter, the luminescence intensity was measured using a luminometer (ALOKA).
  • Separately, the magnetic particles produced in Example 2 was aminosilanated, then carboxylated, and then, anti-AFP antibodies were bound to the particles, which were then used for assaying AFP. The obtained results are shown in Figs. 5, 6 and 7. Signal values are given in Fig. 5. blank values (noise values) in Fig. 6, and S/N ratios in Fig. 7.
  • Example 11 [Maleimidation of gelatin-coated magnetic particles]
  • A 20-mg portion of the gelatin-coated magnetic particles prepared in Example 3 was dispersed in 4 ml of 100 mM sodium phosphate buffer (pH 7.0), and 2 ml of a GMBS solution (1 mg/ml, ethanol) was added, and the mixture was stirred in an end-over-end manner. After an hour, 2 ml of the same GMBS solution was added and the mixture was stirred in an end-over-end manner. After an hour, the particles were washed three times with ethanol and further three times with 100 mM sodium phosphate buffer (pH 7.0).
  • Example 12 [Preparation of TP antigen bound particles]
  • Three point five µg of iminothiolane was added to 350 µl of antigen solution (300 µg/ml, 50 mM aqueous sodium hydrogen carbonate, pH 8.2) of a Treponema pallidum (TP) in a solution form. After allowing the reaction to proceed at 37 °C for 30 minutes, the buffer was replaced with 50 mM potassium phosphate buffer (1 mM EDTA·2Na, pH 7.0) using PD-10 (Pharmacia). In this mixture, 3.5 mg of the maleimidated particles prepared in Example 11 were dispersed. After 2 hours of stirring using an end-over-end mixer, the particles were washed three times with 50 mM sodium phosphate buffer (1 mM EDTA·2Na, pH 7.0) and further three times with a 2% BSA solution (50 mM Tris-hydrochloride, 0.15 M sodium chloride, 1 mM EDTA·2Na, pH 7.2) and then were dispersed in the same 2% BSA solution to give a TP antigen bound particle dispersion.
  • Example 13 [Antibody detection assay using TP antigen bound particles]
  • In a cartridge, 20 µl of a 10-fold dilution of positive serum for anti-TP antibody was mixed with 350 µl of the 0.01% dispersion of the particles bound TP antigens which was prepared in Example 12, and the reaction was allowed to proceed at 37°C for 10 minutes. The cartridge was contacted with a magnet with a surface magnetic field with strength of 3000 gauss for magnetic separation of the particles, and the supernatant was discarded by decantation. Then, 300 µl of physiological saline was added, and the mixture was stirred. The cartridge was drained in the same manner as mentioned above. This procedure was repeated three times. Then, 250 µl of the solution of an alkaline phosphatase bound anti-human antibody (0.2 µg/ml, 50 mM Mes-sodium salt, pH 6.8) was added, and the reaction was allowed to proceed at 37°C for 10 minutes. The cartridge was then washed in the same manner as mentioned above. To the particle-containing cartridge was added 200 µl of a substrate solution containing 200 µg/ml of the luminescent substrate AMPPD (0.1 M DEA-hydrochloride, 1 mM MgCl₂, pH 10.0), and the reaction was allowed to proceed at 37°C for 5 minutes. Thereafter, the luminescence intensity was measured using a luminometer (ALOKA).
  • The obtained signal value is shown in Fig. 8, the blank value (noise value) in Fig. 9 and the S/N ratio in Fig. 10.
  • INDUSTRIAL APPLICABILITY
  • The magnetic particles to be used in immunoassay in accordance with this invention are each composed of a core essentailly consisting of organic polymer materials, a magnetic material layer coating the core, and gelatin on the surface of said magnetic material layer and, therefore, are substantially free of iron migration and very stable against a prolonged period of storage. They are excellent in magnetic response and hardly undergo self aggregation, so that they can be expected to conform satisfactorily to rapid B/F separation and washing requirements. Therefore, the method of this invention can give low-noise, high-signal assay results.

Claims (7)

  1. A gelatin-coated magnetic particle which comprises a core comprising an organic polymer material, a magnetic material layer coating the surface of said core, and a gelatin layer coating the surface of said magnetic material layer, said particle having a diameter of 1.0 to 10 µm.
  2. The gelatin-coated magnetic particle according to Claim 1, wherein said core has a diameter of 0.1 to 5 µm.
  3. A gelatin-coated magnetic particle according to Claim 1 or 2, wherein said an organic polymer material comprises at least one member selected from the group consisting of polystyrene, polymethacrylic esters, polyacrylic esters, styrene-methacrylic ester copolymers, styrene-acrylic ester copolymers, polymerized silanes and organic silanes.
  4. An immunoassay method using gelatin-coated magnetic particles comprising a core comprising an organic polymer material, a magnetic material layer coating the surface of said core, and a gelatin layer coating the surface of said magnetic material layer, said particles having a diameter of 1.0 to 10 µm.
  5. An immunoassay method according to Claim 4, wherein said core has a diameter of 0.1 to 5 µm.
  6. An immunoassay method according to Claim 4 or 5, wherein said organic polymer material comprises at least one member selected from the group consisting of polystyrene, polymethacrylic esters, polyacrylic esters, styrene-methacrylic ester copolymers, styrene-acrylic ester copolymers, polymerized silanes and organic silanes.
  7. An immunoassay method according to Claim 4, 5 or 6, wherein labeled antigens or antibodies are used.
EP94919875A 1993-07-08 1994-07-08 Magnetic particles covered with gelatin and immunoassay using the same Expired - Lifetime EP0709680B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP19318493 1993-07-08
JP19318493 1993-07-08
JP193184/93 1993-07-08
PCT/JP1994/001120 WO1995002185A1 (en) 1993-07-08 1994-07-08 Magnetic particles with gelatin and immunoassay using the same

Publications (3)

Publication Number Publication Date
EP0709680A1 true EP0709680A1 (en) 1996-05-01
EP0709680A4 EP0709680A4 (en) 1998-04-29
EP0709680B1 EP0709680B1 (en) 2001-09-26

Family

ID=16303706

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94919875A Expired - Lifetime EP0709680B1 (en) 1993-07-08 1994-07-08 Magnetic particles covered with gelatin and immunoassay using the same

Country Status (7)

Country Link
EP (1) EP0709680B1 (en)
JP (1) JP3192149B2 (en)
AU (1) AU681893B2 (en)
CA (1) CA2166705C (en)
DE (1) DE69428445T2 (en)
ES (1) ES2164710T3 (en)
WO (1) WO1995002185A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0643305A2 (en) * 1993-09-13 1995-03-15 Ciba Corning Diagnostics Corp. Undercoating of solid phase surfaces and direct coating method
FR2773416A1 (en) * 1998-01-06 1999-07-09 Bio Merieux IMPROVED MAGNETIC PARTICLES, METHODS OF OBTAINING THEM AND USES THEREOF IN THE SEPARATION OF MOLECULES
EP1108743A2 (en) * 1999-12-08 2001-06-20 JSR Corporation Virus-binding particles, virus-separating reagent, separation of viruses, and detection of viruses
EP1400808A1 (en) * 2001-05-18 2004-03-24 Srl, Inc. Immunoassay method
GB2436003A (en) * 2005-12-06 2007-09-12 Trinity Res Ltd A method for preparing a microbead suspension for use in an assay for determining the presence of antibodies to human immunodeficiency virus
WO2009151148A1 (en) * 2008-06-12 2009-12-17 Canon Kabushiki Kaisha Composite particle, method for producing the same, dispersion solution, magnetic biosensing apparatus and magnetic biosensing method
WO2016057617A1 (en) * 2014-10-08 2016-04-14 Avioq, Inc. Methods for simultaneous determination of serological profile and estimation of duration post hiv infection
CN112034159A (en) * 2020-09-06 2020-12-04 武汉生之源生物科技股份有限公司 Gelled immunomagnetic beads and preparation method and application thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007085929A (en) * 2005-09-22 2007-04-05 Jsr Corp Magnetic particles for specific capturing and its manufacturing method
CN102426249A (en) * 2011-08-31 2012-04-25 内蒙古科慧生物科技有限责任公司 Kit for quantitatively determining thyroid stimulating hormone (TSH) and detection method for TSH
CN102507917A (en) * 2011-11-01 2012-06-20 四川金域医学检验中心有限公司 Valproic acid homogeneous-phase enzyme immunity rapid detection kit
US20200338218A1 (en) * 2017-11-06 2020-10-29 Yasuhiko Tabata Hydrogel particle and method for producing same, cell or cell structure each enclosing hydrogel particle therein, method for evaluating activity of cell using hydrogel particle, and use of hydrogel particle as sustained release preparation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008134A1 (en) * 1990-10-31 1992-05-14 Coulter Corporation Biodegradable particle coatings having a protein covalently immobilized by a crosslinking agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2334106A1 (en) * 1975-12-02 1977-07-01 Pasteur Institut MAGNETIC GEL SUITABLE FOR IMMUNOENZYMATIC DOSAGE
JPS59195161A (en) * 1983-04-21 1984-11-06 Fujirebio Inc Magnetic particle and its production
US4965007A (en) * 1988-05-10 1990-10-23 Eastman Kodak Company Encapsulated superparamagnetic particles
JP2979414B2 (en) * 1989-09-29 1999-11-15 富士レビオ株式会社 Magnetic particles and immunoassay using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008134A1 (en) * 1990-10-31 1992-05-14 Coulter Corporation Biodegradable particle coatings having a protein covalently immobilized by a crosslinking agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9502185A1 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0643305A2 (en) * 1993-09-13 1995-03-15 Ciba Corning Diagnostics Corp. Undercoating of solid phase surfaces and direct coating method
FR2773416A1 (en) * 1998-01-06 1999-07-09 Bio Merieux IMPROVED MAGNETIC PARTICLES, METHODS OF OBTAINING THEM AND USES THEREOF IN THE SEPARATION OF MOLECULES
WO1999035500A1 (en) * 1998-01-06 1999-07-15 Bio Merieux Improved magnetic particles, method for obtaining same and uses for separating molecules
US6521341B1 (en) 1998-01-06 2003-02-18 Bio Merieux Magnetic particles, method for obtaining same and uses for separating molecules
EP1108743A2 (en) * 1999-12-08 2001-06-20 JSR Corporation Virus-binding particles, virus-separating reagent, separation of viruses, and detection of viruses
EP1108743A3 (en) * 1999-12-08 2002-02-06 JSR Corporation Virus-binding particles, virus-separating reagent, separation of viruses, and detection of viruses
EP1400808A1 (en) * 2001-05-18 2004-03-24 Srl, Inc. Immunoassay method
EP1400808A4 (en) * 2001-05-18 2004-06-16 Srl Inc Immunoassay method
GB2436003A (en) * 2005-12-06 2007-09-12 Trinity Res Ltd A method for preparing a microbead suspension for use in an assay for determining the presence of antibodies to human immunodeficiency virus
GB2436003B (en) * 2005-12-06 2011-01-05 Trinity Res Ltd A method for preparing a microbead suspension for use in an assay for determining the presence of antibodies to HIV in a sample and an assay
WO2009151148A1 (en) * 2008-06-12 2009-12-17 Canon Kabushiki Kaisha Composite particle, method for producing the same, dispersion solution, magnetic biosensing apparatus and magnetic biosensing method
WO2016057617A1 (en) * 2014-10-08 2016-04-14 Avioq, Inc. Methods for simultaneous determination of serological profile and estimation of duration post hiv infection
US11709163B2 (en) * 2014-10-08 2023-07-25 Avioq, Inc. Methods for simultaneous determination of serological profile and estimation of duration post HIV infection
CN112034159A (en) * 2020-09-06 2020-12-04 武汉生之源生物科技股份有限公司 Gelled immunomagnetic beads and preparation method and application thereof
CN112034159B (en) * 2020-09-06 2023-08-29 武汉生之源生物科技股份有限公司 Gelating immunomagnetic bead and preparation method and application thereof

Also Published As

Publication number Publication date
EP0709680A4 (en) 1998-04-29
ES2164710T3 (en) 2002-03-01
AU7084594A (en) 1995-02-06
CA2166705A1 (en) 1995-01-19
DE69428445T2 (en) 2002-05-29
EP0709680B1 (en) 2001-09-26
AU681893B2 (en) 1997-09-11
WO1995002185A1 (en) 1995-01-19
CA2166705C (en) 2004-11-09
DE69428445D1 (en) 2001-10-31
JP3192149B2 (en) 2001-07-23

Similar Documents

Publication Publication Date Title
EP0420186B1 (en) Immunoassay using magnetic particle
US5736349A (en) Magnetic particle and immunoassay using the same
CA2260991C (en) Multiplex flow immunoassays with magnetic particles as solid phase
US6013531A (en) Method to use fluorescent magnetic polymer particles as markers in an immunoassay
JP2762259B2 (en) How to use magnetically responsive fluorescent polymer
US5395688A (en) Magnetically responsive fluorescent polymer particles
US5283079A (en) Process to make magnetically responsive fluorescent polymer particles
JP2736467B2 (en) Manufacturing method of magnetically responsive polymer particles and its application
EP0709680B1 (en) Magnetic particles covered with gelatin and immunoassay using the same
JPS6338668B2 (en)
CA2060194A1 (en) Manipulation of colloids for facilitating magnetic separations
JPS62190466A (en) Method of separating particle
US4138213A (en) Agglutination immunoassay of immune complex with RF or Clq
JPH09504094A (en) Method for assaying immunological substances using magnetic latex particles and non-magnetic particles
CA1136400A (en) Particulate reagents for use in immunoassays
JPH06231957A (en) Particle coated with ferrite and its manufacture
EP0585868B1 (en) Magnetic particle and immunoassay using the same
JP2844263B2 (en) Method for producing magnetically responsive polymer particles and use thereof
JPH0843391A (en) Measuring method for antigen antibody reaction
US6143575A (en) Heterogeneous immunoassay using a precipitable solid phase
JPH0772155A (en) Method for measuring antigen-antibody reaction
JPH0792168A (en) Immunoassay and particle therefor
CA1339545C (en) Process for producing magnetically responsive polymer particles and applications thereof
JP4359416B2 (en) Measuring method of substance immobilized on microparticle solid phase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 19980312

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE ES FR GB IT LI NL

17Q First examination report despatched

Effective date: 20000211

RTI1 Title (correction)

Free format text: MAGNETIC PARTICLES COVERED WITH GELATIN AND IMMUNOASSAY USING THE SAME

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RTI1 Title (correction)

Free format text: MAGNETIC PARTICLES COVERED WITH GELATIN AND IMMUNOASSAY USING THE SAME

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): CH DE ES FR GB IT LI NL

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69428445

Country of ref document: DE

Date of ref document: 20011031

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

ET Fr: translation filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2164710

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: FUJIREBIO INC.

Free format text: MIRACA HOLDINGS INC.#62-5, NIHONBASHI HAMACHO 2-CHOME CHUO-KU#TOKYO (JP) -TRANSFER TO- FUJIREBIO INC.#62-5, NIHONBASHI HAMACHO 2-CHOME CHUO-KU#TOKYO (JP)

Ref country code: CH

Ref legal event code: PFA

Owner name: MIRACA HOLDINGS INC.

Free format text: FUJIREBIO INC.#7-1, NISHI-SHINJUKU 2-CHOME#SHINJUKU-KU, TOKYO 163-07 (JP) -TRANSFER TO- MIRACA HOLDINGS INC.#62-5, NIHONBASHI HAMACHO 2-CHOME CHUO-KU#TOKYO (JP)

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Ref country code: FR

Ref legal event code: CD

NLS Nl: assignments of ep-patents

Owner name: FUJIREBIO INC.

Effective date: 20070402

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: MIRACA HOLDINGS INC.

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20100716

Year of fee payment: 17

Ref country code: ES

Payment date: 20100722

Year of fee payment: 17

Ref country code: CH

Payment date: 20100714

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20100719

Year of fee payment: 17

Ref country code: FR

Payment date: 20100805

Year of fee payment: 17

Ref country code: DE

Payment date: 20100630

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100707

Year of fee payment: 17

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: FUJIREBIO INC.

Free format text: FUJIREBIO INC.#62-5, NIHONBASHI HAMACHO 2-CHOME CHUO-KU#TOKYO (JP) -TRANSFER TO- FUJIREBIO INC.#62-5, NIHONBASHI HAMACHO 2-CHOME CHUO-KU#TOKYO (JP)

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20120201

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110708

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120201

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110731

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110801

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69428445

Country of ref document: DE

Effective date: 20120201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120201

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110708

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20121122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110709